Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Journal of Pediatrics

Volumn 143, Issue 4, 2003, Pages 532-540

  Feltes, Timothy F ^a   Cabalka, Allison K ^b   Meissner, H Cody ^b   Piazza, Franco M ^b   Carlin, David A ^b   Top Jr , Franklin H ^b   Connor, Edward M ^b   Sondheimer, Henry M ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ARTICLE; CHILD; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEART ARRHYTHMIA; HEART SURGERY; HEMODYNAMICS; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TREATMENT PLANNING; VIRUS INFECTION;

EID: 0242298724     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0022-3476(03)00454-2     Document Type: Article

References (18)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children. JAMA 1999;282:1440-6.
2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
4. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002;96:S9-14.
5. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffen MR. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J Pediatr 2000;137:865-70.
6. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
7. Navas L, Wang E, de Carvalho V, Robinson J. Pediatric Investigators Collaborative Network on Infections in Canada: improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-54.
8. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-13.
9. Khongphatthanayothin A, Wong PC, Samara Y, Newth CJL, Wells WJ, Starnes VA, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease; postoperative course and outcome. Crit Care Med 1999;27:1974-81.
10. Altman CA, Englund JA, Demmler G, Drescher KL, Alexander MA, Watrin C, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8.
11. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
12. Simoes EAF, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998;133:492-9.
13. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
14. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
15. th edition. Elk Grove Village, Ill: American Academy of Pediatrics; 2000. p. 483-7.
16. Saez-Llorens X, Castano E, Null D, Steichen J, Sanchez PJ, Ramilo O, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998;17:787-91.
17. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966;83:299-313.
18. American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious